Epigral's Q3 FY 2025-26 Quarterly Results

Result Summary

• Epigral Ltd reported a 2.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 7.2%.
• Its expenses for the quarter were up by 5.6% QoQ and 10.6% YoY.
• The net profit decreased 23.6% QoQ and decreased 62.3% YoY.
• The earnings per share (EPS) of Epigral Ltd stood at 9.07 during Q3 FY 2025-26.

Financial Statments for Q3 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Epigral Ltd operates within a specific industry, providing products or services that cater to a particular market need. However, detailed information regarding the company's primary offerings, industry specifics, or any recent major developments is not available within the provided data. Without additional context or external research, we focus on the financial performance data for this analysis. The financial data presented gives insight into the operational and financial dynamics of Epigral Ltd for the specified quarters.

Revenue

In Q3FY26, Epigral Ltd reported a total income of ₹602.68 crores. When compared to the previous quarter (Q2FY26), this represents a quarter-over-quarter (QoQ) increase of 2.3%. However, on a year-over-year (YoY) basis, comparing Q3FY26 to Q3FY25, there is a notable decline of 7.2% as the total income for Q3FY25 was ₹649.10 crores. This reduction in revenue over the year may be indicative of changing market dynamics or other influences affecting the company's revenue generation capabilities.

Profitability

The profitability metrics for Epigral Ltd show a decline both sequentially and annually. The profit before tax in Q3FY26 was ₹54.60 crores, which is a decrease of 21.9% from Q2FY26 and a significant drop of 64.4% from Q3FY25, where the profit before tax was ₹153.53 crores. Similarly, the profit after tax for Q3FY26 stood at ₹39.11 crores, marking a 23.6% decrease from the previous quarter and a 62.3% decrease from the same quarter last year. This decline in profitability is also reflected in the earnings per share, which dropped from 24.25 in Q3FY25 to 9.07 in Q3FY26, representing a YoY decrease of 62.6% and a QoQ decrease of 23.6%.

Operating Metrics

The total expenses for Epigral Ltd in Q3FY26 were ₹548.08 crores, showing a QoQ increase of 5.6% from Q2FY26 where the expenses were ₹519.15 crores. On a YoY basis, the expenses increased by 10.6% as compared to ₹495.57 crores in Q3FY25. The tax expense also decreased by 16.2% QoQ and 69.1% YoY, from ₹18.43 crores in Q2FY26 to ₹15.45 crores in Q3FY26, and from ₹49.99 crores in Q3FY25. These variations in expenses and tax liabilities contribute to the overall financial performance of Epigral Ltd for the reported periods.